A study published in a US medical journal last weekend found that those who were severely overweight and took a new drug called Tirzepatide, which is given by subcutaneous injection into the abdomen once a week, lost up to 24 kg a year and a half (average 22.5%). From their weight).
"Obesity requires the care of a multi-professional team."
The subject has nothing to do with the news,
The study involved 2,539 people from around the world, who are overweight and have another non-diabetic background disease.
Half received thyrazeptide treatment, and half a placebo.
After 72 weeks, participants achieved an average decrease of between 16 kg (low dose of 5 mg) and 24 kg (high dose of 15 mg).
The control group given a placebo lost only 2 kg. 85% to 91% of the participants lost more than 5% of their weight, depending on the dose they received.
The drug belongs to a group of diabetes drugs based on natural hormones, which reduce appetite.
The side effects reported were mild to moderate in severity.
According to experts, the drug shows better results than its competitors and may become a hit, revolutionize the field and even save gastric bypass surgery.
All that remains is to get the approval of the US Food and Drug Administration (FDA).
"The research findings of the new drug represent a real revolution in the treatment of obesity," says Dr. Raz Hagoel, a specialist and medical director of the Center for the Treatment of Obesity.
"It is now clear that obesity is a disease that requires treatment by a multidisciplinary team, which includes doctors and nutritionists who specialize in treating obesity, while tailoring the treatment to the patient individually."
Were we wrong?
Fixed!
If you found an error in the article, we'll be happy for you to share it with us